We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

116 hedge funds and large institutions have $764M invested in BioCryst Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 39 increasing their positions, 26 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

130% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 10

100% more funds holding in top 10

Funds holding in top 10: 2 → 4 (+2)

52% more capital invested

Capital invested by funds: $501M → $764M (+$263M)

50% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 26

28% more call options, than puts

Call options by funds: $1.86M | Put options by funds: $1.46M

13% more funds holding

Funds holding: 103 → 116 (+13)

3.02% more ownership

Funds ownership: 88.53% → 91.56% (+3%)

Holders
116
Holders Change
+13
Holders Change %
+12.62%
% of All Funds
2.65%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.09%
New
23
Increased
39
Reduced
26
Closed
10
Calls
$1.86M
Puts
$1.46M
Net Calls
+$404K
Net Calls Change
-$84K

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$15.1M
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$7.75M
3
BBA
Baker Bros. Advisors
New York
+$7.33M
4
EAM
Eventide Asset Management
Massachusetts
+$7.03M
5
BlackRock
BlackRock
New York
+$6.81M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$4.47M
2
Millennium Management
Millennium Management
New York
-$3.46M
3
State Street
State Street
Massachusetts
-$1.89M
4
Renaissance Technologies
Renaissance Technologies
New York
-$1.19M
5
OAM
Oxford Asset Management
United Kingdom
-$689K
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
26
JP Morgan Chase
New York
$2.93M +$2.39M +355,418 +1,263%
TA
27
Teachers Advisors
New York
$2.25M +$78.5K +11,682 +4%
Allianz Asset Management
28
Allianz Asset Management
Germany
$2.12M +$322K +48,005 +21%
CAM
29
ClariVest Asset Management
California
$1.85M -$41.6K -6,200 -2%
Hudson Bay Capital Management
30
Hudson Bay Capital Management
Connecticut
$1.68M -$537K -80,000 -27%
Renaissance Technologies
31
Renaissance Technologies
New York
$1.66M -$1.19M -177,378 -45%
Two Sigma Advisers
32
Two Sigma Advisers
New York
$1.51M +$195K +29,000 +17%
Morgan Stanley
33
Morgan Stanley
New York
$1.47M -$326K -48,610 -20%
California State Teachers Retirement System (CalSTRS)
34
California State Teachers Retirement System (CalSTRS)
California
$1.27M +$109K +16,224 +11%
EP
35
Eversept Partners
New York
$1.14M – – –
Two Sigma Investments
36
Two Sigma Investments
New York
$1.13M +$45.9K +6,828 +5%
Goldman Sachs
37
Goldman Sachs
New York
$1.1M +$307K +45,674 +46%
RA
38
Royce & Associates
New York
$1.1M – – –
Citigroup
39
Citigroup
New York
$953K +$264K +39,265 +46%
Swiss National Bank
40
Swiss National Bank
Switzerland
$916K – – –
California Public Employees Retirement System
41
California Public Employees Retirement System
California
$914K +$70K +10,421 +10%
AllianceBernstein
42
AllianceBernstein
Tennessee
$888K – – –
UBS Group
43
UBS Group
Switzerland
$854K +$327K +48,646 +77%
New York State Common Retirement Fund
44
New York State Common Retirement Fund
New York
$777K – – –
PVI
45
Pura Vida Investments
New York
$773K +$680K +101,245 New
State of Wisconsin Investment Board
46
State of Wisconsin Investment Board
Wisconsin
$765K – – –
CCMU
47
Cheyne Capital Management (UK)
United Kingdom
$763K – – –
OAM
48
Oxford Asset Management
United Kingdom
$747K -$689K -102,637 -51%
RhumbLine Advisers
49
RhumbLine Advisers
Massachusetts
$718K -$6.01K -895 -0.9%
VEA
50
Virtus ETF Advisers
New York
$637K -$401K -59,662 -42%
1
2
3 4 5

BCRX Hedge Fund Activity: Q3 2018 in Review

116 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q3 2018, worth a combined $764M — up 52% from $501M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new BCRX positions and 10 closed out — a net gain of 13 holders — while 39 added to existing stakes and 26 trimmed.

The largest buyer was RA Capital Management, adding an estimated $15.1M. The largest seller was Fidelity Investments, cutting an estimated $4.47M.

  • 116 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q3 2018, up from 103 in Q2 2018.
  • Funds reported $764M of BioCryst Pharmaceuticals stock for Q3 2018, up 52% quarter-over-quarter.
  • 23 funds opened new BioCryst Pharmaceuticals positions in Q3 2018 and 10 closed out, a net change of +13 holders.
  • The largest BioCryst Pharmaceuticals buyer in Q3 2018 was RA Capital Management, an estimated $15.1M added.
  • The largest BioCryst Pharmaceuticals seller in Q3 2018 was Fidelity Investments, an estimated $4.47M sold.

Based on aggregated 13F filings for Q3 2018.